Abstract:Abstract Receptor activator of NF‐κB ligand (RANKL) stimulation leads to the activation of mitogen‐activated protein kinase (MAPK)/AP‐1 and Ca 2+ –nuclear factor of activated T‐cells cytoplasmic 1 (NFATc1) signaling pathways in osteoclastogenesis. Targeting these pathways has been an encouraging strategy for bone‐related diseases, such as postmenopausal osteoporosis. In this study, we examined the effects of caffeic acid 3,4‐dihydroxy‐phenethyl ester (CADPE) on osteoclastogenesis. In mouse bone marrow monocytes (BMMs) and RAW264.7 cells, CADPE suppressed RANKL‐induced osteoclast differentiation and actin‐ring formation in a dose‐dependent manner within non–growth inhibitory concentrations at the early stage, while CADPE had no effect on macrophage colony‐stimulating factor (M‐CSF)‐induced proliferation and differentiation. At the molecular level, CADPE inhibited RANKL‐induced phosphorylation of MAPKs, including extracellular signal‐regulated kinases 1/2 (ERK1/2), p38, and c‐Jun N‐terminal kinase (JNK), without significantly affecting the NF‐κB signaling pathway. CADPE abrogated RANKL‐induced activator protein 1 (AP‐1)/FBJ murine osteosarcoma viral oncogene homolog (c‐Fos) nuclear translocation and activation. Overexpression of c‐Fos prevented the inhibition by CADPE of osteoclast differentiation. Furthermore, CADPE suppressed RANKL‐induced the tumor necrosis factor receptor associated factor 6 (TRAF6) interaction with c‐src tyrosine kinase (c‐Src), blocked RANKL‐induced the phosphorylation of protein kinase B (AKT), and inhibited RANKL‐induced Ca 2+ oscillation. As a result, CADPE decreased osteoclastogenesis‐related marker gene expression, including NFATc1 , TRAP , cathepsin K , and c‐Src . To test the effects of CADPE on osteoclast activity in vivo, we showed that CADPE prevented ovariectomy‐induced bone loss by inhibiting osteoclast activity. Together, our data demonstrate that CADPE suppresses osteoclastogenesis and bone loss through inhibiting RANKL‐induced MAPKs and Ca 2+ ‐NFATc1 signaling pathways. CADPE is a novel agent in the treatment of osteoclast‐related diseases, such as osteoporosis. © 2012 American Society for Bone and Mineral Research.

Dual Targeting of SREBP2 and ERRα by Carnosic Acid Suppresses RANKL-mediated Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss.

Cirsilineol inhibits RANKL-induced osteoclast activity and ovariectomy-induced bone loss via NF-κb/ERK/p38 signaling pathways

Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss Via Suppressing Osteoclastogenesis in Mice

Carnosol Attenuates RANKL-induced Osteoclastogenesis in Vitro and LPS-induced Bone Loss.

Cirsilineol inhibits RANKL-induced osteoclast activity and ovariectomy-induced bone loss via NK-κβ/ERK/p38 signaling pathways

Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+-nuclear fact

Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy‐induced bone loss

Calycosin attenuates osteoporosis and regulates the expression of OPG/RANKL in ovariectomized rats via MAPK signaling

Madecassoside Inhibits Estrogen Deficiency‐induced Osteoporosis by Suppressing RANKL‐induced Osteoclastogenesis

Carnosol Suppresses RANKL-induced Osteoclastogenesis and Attenuates Titanium Particles-Induced Osteolysis.

Cepharanthine Prevents Estrogen Deficiency-Induced Bone Loss by Inhibiting Bone Resorption

Carnosic Acid Alleviates Hyperlipidemia and Insulin Resistance by Promoting the Degradation of SREBPs Via the 26S Proteasome

Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-B, Calcium, and NFATc1 Pathways

Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways

Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity

Enhanced Efficiency of Calcium-Derived Oleoyl Serine on Osteoporosis Via Wnt/β-catenin Pathway.

Suppressing ERp57 diminishes osteoclast activity and ameliorates ovariectomy-induced bone loss via the intervention in calcium oscillation and the calmodulin/calcineurin/Nfatc1 pathway

18Β-Glycyrrhetinic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANKL-Mediated RANK–TRAF6 Interactions and NF-κB and MAPK Signaling Pathways

Corylifol A protects against ovariectomized-induced bone loss and attenuates RANKL-induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation

Oxyresveratrol attenuates bone resorption by inhibiting the mitogen-activated protein kinase pathway in ovariectomized rats